{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:47:22Z","timestamp":1740138442177,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s12020-020-02483-2","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T06:52:30Z","timestamp":1599720750000},"page":"199-207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inhibition of the RANKL with denosumab has no effect on circulating markers of atherosclerosis in women with postmenopausal osteoporosis: a pilot study"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0141-1202","authenticated-orcid":false,"given":"Cristiana","family":"Cipriani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Piemonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Colangelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Diacinti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Ferrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Piazzolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Fassino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Nieddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"issue":"1","key":"2483_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13075-018-1805-7","volume":"21","author":"Z Szekanecz","year":"2019","unstructured":"Z. Szekanecz, H.G. Raterman, Z. Petho, W.F. Lems, Common mechanisms and holistic care in atherosclerosis and osteoporosis. Arthritis Res. Ther. 21(1), 15 (2019). https:\/\/doi.org\/10.1186\/s13075-018-1805-7","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"2483_CR2","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1359\/JBMR.050711","volume":"20","author":"LB Tanko","year":"2005","unstructured":"L.B. Tanko, C. Christiansen, D.A. Cox, M.J. Geiger, M.A. McNabb, S.R. Cummings, Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res. 20(11), 1912\u20131920 (2005). https:\/\/doi.org\/10.1359\/JBMR.050711","journal-title":"J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res."},{"issue":"3","key":"2483_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-006-0282-z","volume":"18","author":"LC Hofbauer","year":"2007","unstructured":"L.C. Hofbauer, C.C. Brueck, C.M. Shanahan, M. Schoppet, H. Dobnig, Vascular calcification and osteoporosis-from clinical observation towards molecular understanding. Osteoporos. Int. 18(3), 251\u2013259 (2007). https:\/\/doi.org\/10.1007\/s00198-006-0282-z","journal-title":"Osteoporos. Int."},{"key":"2483_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2018.08.046","volume":"278","author":"AB Reiss","year":"2018","unstructured":"A.B. Reiss, N. Miyawaki, J. Moon, L.J. Kasselman, I. Voloshyna, R. D\u2019Avino Jr., J. De Leon, CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies. Atherosclerosis 278, 49\u201359 (2018). https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.08.046","journal-title":"Atherosclerosis"},{"issue":"4","key":"2483_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00223-013-9712-z","volume":"93","author":"M Wu","year":"2013","unstructured":"M. Wu, C. Rementer, C.M. Giachelli, Vascular calcification: an update on mechanisms and challenges in treatment. Calcif. Tissue Int. 93(4), 365\u2013373 (2013). https:\/\/doi.org\/10.1007\/s00223-013-9712-z","journal-title":"Calcif. Tissue Int."},{"issue":"6","key":"2483_CR6","doi-asserted-by":"publisher","first-page":"R297","DOI":"10.1530\/EJE-17-0485","volume":"177","author":"J Pepe","year":"2017","unstructured":"J. Pepe, C. Cipriani, C. Sonato, O. Raimo, F. Biamonte, S. Minisola, Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur. J. Endocrinol. 177(6), R297\u2013R308 (2017). https:\/\/doi.org\/10.1530\/EJE-17-0485","journal-title":"Eur. J. Endocrinol."},{"issue":"6","key":"2483_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1053\/j.ackd.2019.09.004","volume":"26","author":"M Ray","year":"2019","unstructured":"M. Ray, A. Jovanovich, Mineral bone abnormalities and vascular calcifications. Adv. Chronic Kidney Dis. 26(6), 409\u2013416 (2019). https:\/\/doi.org\/10.1053\/j.ackd.2019.09.004","journal-title":"Adv. Chronic Kidney Dis."},{"issue":"5-6","key":"2483_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s001090100226","volume":"79","author":"LC Hofbauer","year":"2001","unstructured":"L.C. Hofbauer, A.E. Heufelder, Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J. Mol. Med. 79(5-6), 243\u2013253 (2001). https:\/\/doi.org\/10.1007\/s001090100226","journal-title":"J. Mol. Med."},{"issue":"1","key":"2483_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00223-003-0011-y","volume":"74","author":"AM Sattler","year":"2004","unstructured":"A.M. Sattler, M. Schoppet, J.R. Schaefer, L.C. Hofbauer, Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif. tissue Int. 74(1), 103\u2013106 (2004). https:\/\/doi.org\/10.1007\/s00223-003-0011-y","journal-title":"Calcif. tissue Int."},{"key":"2483_CR10","doi-asserted-by":"publisher","unstructured":"L. Rochette, A. Meloux, E. Rigal, M. Zeller, Y. Cottin, C. Vergely, The role of osteoprotegerin and its ligands in vascular function. Int. J. Mol. Sci. 20(3) (2019). https:\/\/doi.org\/10.3390\/ijms20030705","DOI":"10.3390\/ijms20030705"},{"issue":"7","key":"2483_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"H.G. Bone, R.B. Wagman, M.L. Brandi, J.P. Brown, R. Chapurlat, S.R. Cummings, E. Czerwinski, A. Fahrleitner-Pammer, D.L. Kendler, K. Lippuner, J.Y. Reginster, C. Roux, J. Malouf, M.N. Bradley, N.S. Daizadeh, A. Wang, P. Dakin, N. Pannacciulli, D.W. Dempster, S. Papapoulos, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. lancet Diabetes Endocrinol. 5(7), 513\u2013523 (2017). https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"lancet Diabetes Endocrinol."},{"key":"2483_CR12","doi-asserted-by":"publisher","first-page":"115081","DOI":"10.1016\/j.bone.2019.115081","volume":"130","author":"EL Simpson","year":"2020","unstructured":"E.L. Simpson, M. Martyn-St James, J. Hamilton, R. Wong, N. Gittoes, P. Selby, S. Davis, Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone 130, 115081 (2020). https:\/\/doi.org\/10.1016\/j.bone.2019.115081","journal-title":"Bone"},{"issue":"3","key":"2483_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.4158\/EP14106.OR","volume":"21","author":"KC Sheedy","year":"2015","unstructured":"K.C. Sheedy, M.I. Camara, P.M. Camacho, Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis. Endocr. Pract. 21(3), 275\u2013279 (2015). https:\/\/doi.org\/10.4158\/EP14106.OR","journal-title":"Endocr. Pract."},{"key":"2483_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bone.2018.10.001","volume":"120","author":"E Tsourdi","year":"2019","unstructured":"E. Tsourdi, P. Makras, T.D. Rachner, S. Polyzos, M. Rauner, S. Mandanas, L.C. Hofbauer, A.D. Anastasilakis, Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. Bone 120, 44\u201349 (2019). https:\/\/doi.org\/10.1016\/j.bone.2018.10.001","journal-title":"Bone"},{"issue":"2","key":"2483_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2353\/ajpath.2009.080957","volume":"175","author":"S Helas","year":"2009","unstructured":"S. Helas, C. Goettsch, M. Schoppet, U. Zeitz, U. Hempel, H. Morawietz, P.J. Kostenuik, R.G. Erben, L.C. Hofbauer, Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am. J. Pathol. 175(2), 473\u2013478 (2009). https:\/\/doi.org\/10.2353\/ajpath.2009.080957","journal-title":"Am. J. Pathol."},{"issue":"1","key":"2483_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12020-012-9696-x","volume":"42","author":"K Sinningen","year":"2012","unstructured":"K. Sinningen, E. Tsourdi, M. Rauner, T.D. Rachner, C. Hamann, L.C. Hofbauer, Skeletal and extraskeletal actions of denosumab. Endocrine 42(1), 52\u201362 (2012). https:\/\/doi.org\/10.1007\/s12020-012-9696-x","journal-title":"Endocrine"},{"issue":"2","key":"2483_CR17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/jbmr.2043","volume":"29","author":"EJ Samelson","year":"2014","unstructured":"E.J. Samelson, P.D. Miller, C. Christiansen, N.S. Daizadeh, L. Grazette, M.S. Anthony, O. Egbuna, A. Wang, S.R. Siddhanti, A.M. Cheung, N. Franchimont, D.P. Kiel, RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J. Bone Miner. Res. 29(2), 450\u2013457 (2014). https:\/\/doi.org\/10.1002\/jbmr.2043","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"2483_CR18","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/s0002-9149(01)01685-x","volume":"88","author":"L Mosca","year":"2001","unstructured":"L. Mosca, E. Barrett-Connor, N.K. Wenger, P. Collins, D. Grady, M. Kornitzer, E. Moscarelli, S. Paul, T.J. Wright, J.D. Helterbrand, P.W. Anderson, Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am. J. Cardiol. 88(4), 392\u2013395 (2001). https:\/\/doi.org\/10.1016\/s0002-9149(01)01685-x","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"2483_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1161\/CIRCOUTCOMES.108.831198","volume":"1","author":"PW Wilson","year":"2008","unstructured":"P.W. Wilson, M. Pencina, P. Jacques, J. Selhub, R. D\u2019Agostino Sr., C.J. O\u2019Donnell, C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circulation. Cardiovascular Qual. Outcomes 1(2), 92\u201397 (2008). https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.108.831198","journal-title":"Circulation. Cardiovascular Qual. Outcomes"},{"issue":"11","key":"2483_CR20","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.amjcard.2007.01.036","volume":"99","author":"AH Thakore","year":"2007","unstructured":"A.H. Thakore, C.Y. Guo, M.G. Larson, D. Corey, T.J. Wang, R.S. Vasan, R.B. D\u2019Agostino Sr., I. Lipinska, J.F. Keaney Jr., E.J. Benjamin, C.J. O\u2019Donnell, Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framingham Heart Study). Am. J. Cardiol. 99(11), 1598\u20131602 (2007). https:\/\/doi.org\/10.1016\/j.amjcard.2007.01.036","journal-title":"Am. J. Cardiol."},{"issue":"10","key":"2483_CR21","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1161\/STROKEAHA.114.005991","volume":"45","author":"S Okazaki","year":"2014","unstructured":"S. Okazaki, M. Sakaguchi, K. Miwa, S. Furukado, H. Yamagami, Y. Yagita, H. Mochizuki, K. Kitagawa, Association of interleukin-6 with the progression of carotid atherosclerosis: a 9-year follow-up study. Stroke 45(10), 2924\u20132929 (2014). https:\/\/doi.org\/10.1161\/STROKEAHA.114.005991","journal-title":"Stroke"},{"issue":"2","key":"2483_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2174\/1573406411666150928111446","volume":"12","author":"A Kalampogias","year":"2016","unstructured":"A. Kalampogias, G. Siasos, E. Oikonomou, S. Tsalamandris, K. Mourouzis, V. Tsigkou, M. Vavuranakis, T. Zografos, S. Deftereos, C. Stefanadis, D. Tousoulis, Basic mechanisms in atherosclerosis: the role of calcium. Medicinal Chem. 12(2), 103\u2013113 (2016). https:\/\/doi.org\/10.2174\/1573406411666150928111446","journal-title":"Medicinal Chem."},{"issue":"4","key":"2483_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1084\/jem.192.4.463","volume":"192","author":"H Min","year":"2000","unstructured":"H. Min, S. Morony, I. Sarosi, C.R. Dunstan, C. Capparelli, S. Scully, G. Van, S. Kaufman, P.J. Kostenuik, D.L. Lacey, W.J. Boyle, W.S. Simonet, Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp. Med. 192(4), 463\u2013474 (2000). https:\/\/doi.org\/10.1084\/jem.192.4.463","journal-title":"J. Exp. Med."},{"issue":"9","key":"2483_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1161\/CIRCRESAHA.108.189001","volume":"104","author":"S Panizo","year":"2009","unstructured":"S. Panizo, A. Cardus, M. Encinas, E. Parisi, P. Valcheva, S. Lopez-Ongil, B. Coll, E. Fernandez, J.M. Valdivielso, RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circulation Res. 104(9), 1041\u20131048 (2009). https:\/\/doi.org\/10.1161\/CIRCRESAHA.108.189001","journal-title":"Circulation Res."},{"key":"2483_CR25","doi-asserted-by":"publisher","unstructured":"C. L. Chen, N. C. Chen, F. Z. Wu, M. T. Wu, Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study. Osteoporos. Int. (2020). https:\/\/doi.org\/10.1007\/s00198-020-05391-3","DOI":"10.1007\/s00198-020-05391-3"},{"issue":"4","key":"2483_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/jbmr.5650050402","volume":"5","author":"EF Eriksen","year":"1990","unstructured":"E.F. Eriksen, S.F. Hodgson, R. Eastell, S.L. Cedel, W.M. O\u2019Fallon, B.L. Riggs, Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J. Bone Miner. Res. 5(4), 311\u2013319 (1990). https:\/\/doi.org\/10.1002\/jbmr.5650050402","journal-title":"J. Bone Miner. Res."},{"key":"2483_CR27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000486077","volume":"50","author":"C Cipriani","year":"2018","unstructured":"C. Cipriani, J. Pepe, L. Colangelo, S. Minisola, Vitamin D and secondary hyperparathyroid states. Front. Horm. Res. 50, 138\u2013148 (2018). https:\/\/doi.org\/10.1159\/000486077","journal-title":"Front. Horm. Res."},{"issue":"1","key":"2483_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-017-0579-2","volume":"16","author":"A Zmyslowski","year":"2017","unstructured":"A. Zmyslowski, A. Szterk, Current knowledge on the mechanism of atherosclerosis and pro-atherosclerotic properties of oxysterols. Lipids Health Dis. 16(1), 188 (2017). https:\/\/doi.org\/10.1186\/s12944-017-0579-2","journal-title":"Lipids Health Dis."},{"issue":"5","key":"2483_CR29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","volume":"8","author":"JS Leere","year":"2020","unstructured":"J.S. Leere, J. Karmisholt, M. Robaczyk, S. Lykkeboe, A. Handberg, E. Steinkohl, J. Brondum Frokjaer, P. Vestergaard, Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 8(5), 407\u2013417 (2020). https:\/\/doi.org\/10.1016\/S2213-8587(20)30063-2","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"2483_CR30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nm.3084","volume":"19","author":"S Kiechl","year":"2013","unstructured":"S. Kiechl, J. Wittmann, A. Giaccari, M. Knoflach, P. Willeit, A. Bozec, A.R. Moschen, G. Muscogiuri, G.P. Sorice, T. Kireva, M. Summerer, S. Wirtz, J. Luther, D. Mielenz, U. Billmeier, G. Egger, A. Mayr, F. Oberhollenzer, F. Kronenberg, M. Orthofer, J.M. Penninger, J.B. Meigs, E. Bonora, H. Tilg, J. Willeit, G. Schett, Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 19(3), 358\u2013363 (2013). https:\/\/doi.org\/10.1038\/nm.3084","journal-title":"Nat. Med."},{"issue":"4","key":"2483_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2991","volume":"34","author":"N Napoli","year":"2018","unstructured":"N. Napoli, N. Pannacciulli, E. Vittinghoff, D. Crittenden, J. Yun, A. Wang, R. Wagman, A.V. Schwartz, Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial. Diabetes\/Metab. Res. Rev. 34(4), e2991 (2018). https:\/\/doi.org\/10.1002\/dmrr.2991","journal-title":"Diabetes\/Metab. Res. Rev."},{"key":"2483_CR32","doi-asserted-by":"publisher","first-page":"115268","DOI":"10.1016\/j.bone.2020.115268","volume":"134","author":"S Ferrari","year":"2020","unstructured":"S. Ferrari, R. Eastell, N. Napoli, A. Schwartz, L.C. Hofbauer, A. Chines, A. Wang, N. Pannacciulli, S.R. Cummings, Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension. Bone 134, 115268 (2020). https:\/\/doi.org\/10.1016\/j.bone.2020.115268","journal-title":"Bone"},{"issue":"1","key":"2483_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00774-013-0467-4","volume":"32","author":"A Sykiotis","year":"2014","unstructured":"A. Sykiotis, G. Papaioannou, J. Mavropoulos, M. Triantaphyllopoulou, F. Papandroulaki, V. Ktena, S. Thanou, A. Pardalakis, A. Kaltsa, H. Karga, Markers of inflammation after zoledronic acid redosing. J. Bone Miner. Metab. 32(1), 72\u201377 (2014). https:\/\/doi.org\/10.1007\/s00774-013-0467-4","journal-title":"J. Bone Miner. Metab."},{"issue":"5","key":"2483_CR34","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.bone.2012.02.006","volume":"50","author":"AD Anastasilakis","year":"2012","unstructured":"A.D. Anastasilakis, S.A. Polyzos, P. Makras, G.T. Sakellariou, I. Bisbinas, A. Gkiomisi, S. Delaroudis, S. Gerou, I. Ballaouri, D. Oikonomou, S.E. Papapoulos, Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. Bone 50(5), 1130\u20131134 (2012). https:\/\/doi.org\/10.1016\/j.bone.2012.02.006","journal-title":"Bone"},{"key":"2483_CR35","doi-asserted-by":"publisher","unstructured":"T. Diker-Cohen, D. Rosenberg, T. Avni, D. Shepshelovich, G. Tsvetov, A. Gafter-Gvili, Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis. J. Clin. Endocrinol. Metabol. 105(5) (2020). https:\/\/doi.org\/10.1210\/clinem\/dgz322","DOI":"10.1210\/clinem\/dgz322"},{"issue":"2","key":"2483_CR36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","volume":"22","author":"S Ferrari-Lacraz","year":"2011","unstructured":"S. Ferrari-Lacraz, S. Ferrari, Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos. Int. 22(2), 435\u2013446 (2011). https:\/\/doi.org\/10.1007\/s00198-010-1326-y","journal-title":"Osteoporos. Int."},{"issue":"2","key":"2483_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/phy2.224","volume":"2","author":"VH Rao","year":"2014","unstructured":"V.H. Rao, V. Kansal, S. Stoupa, D.K. Agrawal, MMP-1 and MMP-9 regulate epidermal growth factor-dependent collagen loss in human carotid plaque smooth muscle cells. Physiol. Rep. 2(2), e00224 (2014). https:\/\/doi.org\/10.1002\/phy2.224","journal-title":"Physiol. Rep."},{"issue":"1","key":"2483_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1160\/TH11-05-0324","volume":"107","author":"A Quercioli","year":"2012","unstructured":"A. Quercioli, F. Mach, M. Bertolotto, S. Lenglet, N. Vuilleumier, K. Galan, S. Pagano, V. Braunersreuther, G. Pelli, V. Pistoia, G. Bianchi, G. Cittadini, G.L. Viviani, A. Pende, P. Roux-Lombard, A. Thomas, C. Staub, O. Ratib, F. Dallegri, T.H. Schindler, F. Montecucco, Receptor activator of NF- kappaB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thrombosis Haemost. 107(1), 124\u2013139 (2012). https:\/\/doi.org\/10.1160\/TH11-05-0324","journal-title":"Thrombosis Haemost."},{"issue":"5","key":"2483_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063153","volume":"8","author":"S Casimiro","year":"2013","unstructured":"S. Casimiro, K.S. Mohammad, R. Pires, J. Tato-Costa, I. Alho, R. Teixeira, A. Carvalho, S. Ribeiro, A. Lipton, T.A. Guise, L. Costa, RANKL\/RANK\/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS ONE 8(5), e63153 (2013). https:\/\/doi.org\/10.1371\/journal.pone.0063153","journal-title":"PLoS ONE"},{"issue":"6","key":"2483_CR40","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3109\/15412555.2013.813928","volume":"10","author":"PF Zhang","year":"2013","unstructured":"P.F. Zhang, L. Pan, Z.Y. Luo, H.J. Zhao, S.X. Cai, Interrelationship of circulating matrix metalloproteinase-9, TNF-alpha, and OPG\/RANK\/RANKL systems in COPD patients with osteoporosis. COPD 10(6), 650\u2013656 (2013). https:\/\/doi.org\/10.3109\/15412555.2013.813928","journal-title":"COPD"},{"issue":"3","key":"2483_CR41","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/jbmr.3019","volume":"32","author":"NK Choi","year":"2017","unstructured":"N.K. Choi, D.H. Solomon, T.N. Tsacogianis, J.E. Landon, H.J. Song, S.C. Kim, Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study. J. Bone Miner. Res. 32(3), 611\u2013617 (2017). https:\/\/doi.org\/10.1002\/jbmr.3019","journal-title":"J. Bone Miner. Res."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-020-02483-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T23:55:19Z","timestamp":1631058919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-020-02483-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["2483"],"URL":"https:\/\/doi.org\/10.1007\/s12020-020-02483-2","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"type":"print","value":"1355-008X"},{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2020,9,8]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.M. served as speaker for Abiogen, Amgen, Bruno Farmaceutici, Diasorin, Eli Lilly, Shire, Sandoz, Takeda. He served in advisory board of Abiogen, Kyowa Kirin, Pfizer, UCB. All other authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was provided by the independent ethics committee of the \u201cPoliclinico Umberto I\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}